Veeral Sheth to Macular Degeneration
This is a "connection" page, showing publications Veeral Sheth has written about Macular Degeneration.
Connection Strength
1.313
-
An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017 02 01; 48(2):100-104.
Score: 0.503
-
Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Jul; 275:14-26.
Score: 0.220
-
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023 12; 37(17):3574-3581.
Score: 0.194
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
Score: 0.179
-
Reply. Ophthalmol Retina. 2021 01; 5(1):e1-e2.
Score: 0.165
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
Score: 0.052